Viatris maintains legal winning streak with yet another EpiPen antitrust victory

As another round of EpiPen marketing litigation wraps, Mylan’s successor Viatris can chalk up another victory.

Late last week, a federal court in New York tossed investors’ claims against Viatris “in their entirety,” granting the company’s bid for summary judgment in the nearly 7-year-old lawsuit.